Literature DB >> 17074592

Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.

Lorena Ripollés1, Margarita Ortega, Francisco Ortuño, Ana González, Jesús Losada, Jesús Ojanguren, Joan Alfons Soler, Juan Bergua, Maria Dolors Coll, María Rosa Caballín.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the elderly population. Under conventional cytogenetic (CC) analysis, approximately 50% of CLL cases show clonal aberrations. Using fluorescent in situ hybridization (FISH), the percentage of patients with abnormalities rises to almost 80%, the most frequent being 13q14, ATM, and TP53 deletions and trisomy 12. The aim of this study was to establish the incidence of genetic changes in B-CLL patients using CC and FISH and to evaluate the prognostic implications. Of the 65 patients analyzed, genetic aberrations were found in 36.7% with CC and in 68.4% with FISH. The frequencies of abnormalities were as follows: 13q deletion, 42.1%; trisomy 12, 19.2%; ATM deletion, 17.5%; and TP53 deletion, 8.7%. Significant differences were observed when the overall survival was correlated with Rai stage (P = 0.000). FISH abnormalities were correlated with age, sex, morphology, white blood cell count, CD38 expression, Rai stage, disease status, and survival. Significant differences were obtained with age (P = 0.05) and disease status (P = 0.01). Deletion of 13q was the most frequent abnormality (36.6%) among old patients (> or =60); trisomy 12 was the most frequent (31.3%) in younger patients (<60). Half of the patients with stable disease showed 13q deletion, and the most frequent abnormality in patients with progressive disease was ATM deletion (22.2%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074592     DOI: 10.1016/j.cancergencyto.2006.07.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

1.  Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.

Authors:  Xiaobo Zhou; Karl Münger
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles.

Authors:  Carl E G Bruder; Arkadiusz Piotrowski; Antoinet A C J Gijsbers; Robin Andersson; Stephen Erickson; Teresita Diaz de Ståhl; Uwe Menzel; Johanna Sandgren; Desiree von Tell; Andrzej Poplawski; Michael Crowley; Chiquito Crasto; E Christopher Partridge; Hemant Tiwari; David B Allison; Jan Komorowski; Gert-Jan B van Ommen; Dorret I Boomsma; Nancy L Pedersen; Johan T den Dunnen; Karin Wirdefeldt; Jan P Dumanski
Journal:  Am J Hum Genet       Date:  2008-02-14       Impact factor: 11.025

3.  Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer.

Authors:  Ling Wang; Adam J Mosel; Gregory G Oakley; Aimin Peng
Journal:  Mol Cancer Ther       Date:  2012-09-12       Impact factor: 6.261

4.  The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.

Authors:  Ravin Garg; William Wierda; Alessandra Ferrajoli; Lynne Abruzzo; Sherry Pierce; Susan Lerner; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

5.  Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Cancer Res       Date:  2016-12-28       Impact factor: 5.852

Review 6.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

7.  Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Authors:  Paolo Strati; Lynne V Abruzzo; William G Wierda; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-11

Review 8.  Epigenetic alterations in a murine model for chronic lymphocytic leukemia.

Authors:  Shih-Shih Chen; Mara H Sherman; Erin Hertlein; Amy J Johnson; Michael A Teitell; John C Byrd; Christoph Plass
Journal:  Cell Cycle       Date:  2009-11-15       Impact factor: 4.534

9.  The combined status of ATM and p53 link tumor development with therapeutic response.

Authors:  Hai Jiang; H Christian Reinhardt; Jirina Bartkova; Johanna Tommiska; Carl Blomqvist; Heli Nevanlinna; Jiri Bartek; Michael B Yaffe; Michael T Hemann
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

10.  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Authors:  Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.